Federal Circuit Denies Amgen's Rehearing Request

Law360, New York (November 27, 2006, 12:00 AM EST) -- In a setback for drug maker Amgen Inc., the U.S. Court of Appeals for the Federal Circuit has rejected the drug maker’s request that it reconsider a patent infringement ruling partially in favor of rival Aventis Pharmaceuticals Inc.

Amgen wanted a full panel of judges to take a second look at a portion of the court's earlier ruling, issued in August, which reversed a lower court’s decision that Aventis infringed a production patent for the blockbuster anemia drug Epogen.

The lower court ruled that Aventis, along...
To view the full article, register now.